Regulatory T cells in chronic obstructive pulmonary disease;Las células T reguladoras en la enfermedad pulmonar obstructiva crónica

Archivos de Cardiologia de Mexico

Volumn 83, Issue 1, 2013, Pages 45-54

  Limón Camacho, Leonardo ^a   Solleiro Villavicencio, Helena ^a,b   Pupko Sissa, Ilana ^b   Lascurain, Ricardo ^b   Vargas Rojas, María Inés ^b  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

Author keywords

Chronic obstructive pulmonary disease; Immune regulation; Inflammation; Mexico; T regulatory cells; Th17 cells

Indexed keywords

CD4 ANTIGEN; CYTOKINE; TOBACCO SMOKE;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED CLINICAL TRIAL (TOPIC); HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; META ANALYSIS (TOPIC); REGULATORY T LYMPHOCYTE; RISK FACTOR; SYSTEMATIC REVIEW; IMMUNOLOGY; PHYSIOLOGY;

HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; T-LYMPHOCYTES, REGULATORY;

EID: 84875676800     PISSN: 14059940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acmx.2013.01.010     Document Type: Short Survey

References (74)

1. Hodge S, Hodge G. Flow cytometric characterization of cell populations in bronchoalveolar lavage and bronchial brushings from patients with chronic obstructive pulmonary disease. Cytometry B Clin Cytom. 2004;61:27-34.
2. Domagala-Kulawik J. Effects of cigarette smoke on the lung and systemic immunity. J Physiol Pharmacol. 2008;59:19-34.
3. Núñez B, Sauleda J, Antó JM, et al., PAC-COPD Investigators. Anti-tissue antibodies are related to lung function in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011;183:1025-31.
4. Vargas-Rojas MI, Ramírez-Venegas A, Limón-Camacho L, et al. Increase of Th17 cells in peripheral blood of patients with chronic obstructive pulmonary disease. Respir Med. 2011;105:1648-54.
5. Smyth IJ, Starkey C, Vestbo J. CD4-regulatory cells in COPD patients. Chest. 2007;132:156-63.
6. Lee SH, Gosawami S, Grudo A, et al. Antielastin autoimmunity in tobacco smoking-induced emphysema. Nat Med. 2007;13:567-9.
7. Barceló B, Pons J, Ferrer JM, et al. Phenotypic characterisation of T-lymphocytes in COPD: Abnormal CD4+CD25+ regulatory T-lymphocyte response to tobacco smoking. Eur Respir J. 2008;31:555-62.
8. Gershon RK, Kondo K. Cell interactions in the induction of tolerance: The role of thymic lymphocytes. Immunology. 1970;18:723-37.
9. Levings MK, Sangregorio R. Human CD25+CD4+ regulatory T cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med. 2001;193:1295-302.
10. Mosmann TR, Coffman RL. Th1 and Th2 cells: Different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol. 1989;7:145-73.
11. Nishizuka Y, Sakukura T. Thymus and reproduction: Sex-linked dysgenesia of the gonad after neonatal thymectomy in mice. Science. 1969;166:753-5.
12. Sakaguchi S, Fukuma K, Kuribayashi K, et al. Organ-specific autoimmune diseases induced in mice by elimination of T cell subset. I. Evidence for the active participation of T cells in natural self-tolerance; deficit of a T cell subsets a possible cause of autoimmune disease. J Exp Med. 1985;181:72-87.
13. Viguier M, Lemaitre F, Verola O, et al. FoxP3 expressing CD4+CD25high regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the junction of infiltrating T cells. J Immunol. 2004;173:1444-53.
14. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299:1057-61.
15. Bennett CL, Christie J, Ramsdell F, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet. 2001;27:20-1.
16. Gambineri E, Torgerson TR, Ochs HD. Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis. Curr Opin Rheumatol. 2003;15:430-5.
17. Seddon B, Mason D. The third function of the thymus. Immunol Today. 2000;21:95-9.
18. Hsieh CS, Lee HM, Lio CW. Selection of regulatory T cells in the thymus. Nat Rev Immunol. 2012;12:157-67.
19. Khattri R, Cox T. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol. 2003;4:337-42.
20. Loser K, Hansen W, Apelt J, et al. In vitro-generated regulatory T cells induced by Foxp3-retrovirus infection control murine contact allergy and systemic autoimmunity. Gene Ther. 2005;12:1294-304.
21. Munn DH. Indoleamine 2,3-dioxygenase, Tregs and cancer. Curr Med Chem. 2011;18:2240-6.
22. Litjens NH, Boer K, Betjes MG. Identification of circulating human antigen-reactive CD4+ FOXP3+ natural regulatory T cells. J Immunol. 2012;188:1083-90.
23. Chen Y, Adams E, Regateiro FS, et al. Activation rather than Foxp3 expression determines that TGF-_-induced regulatory T cells out-compete naïve T cells in dendritic cell clustering. Eur J Immunol. 2012;42:1436-48.
24. Baecher-Allan C, Brown JA, Freeman GJ, et al. CD4+CD25high regulatory cells in human peripheral blood. J Immunol. 2001;167:1245-53.
25. Dieckmann D, Plottner H, Berchtold S, et al. Ex vivo isolation and characterization of CD4+CD25+ T cells with regulatory properties from human blood. J Exp Med. 2001;193:1303-10.
26. Wild CA, Brandau S, Lindemann M. Toll-like receptors in regulatory T cells of patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2010;136:1253-9.
27. Stope MB, Rönnau C, Schubert T, et al. Transforming growth factor in prostate cancer: Cellular effects and basic molecular mechanisms. Urologe A. 2012;51:1692-6.
28. Gogishvili T, Lühder F, Goebbels S, et al. Cell-intrinsic and-extrinsic control of Treg-cell homeostasis and function revealed by induced CD28 deletion. Eur J Immunol. 2012;43:188-93.
29. Zhou H, Li WM, Zhang M, et al. Foxp3-transfected CD4+ CD25-T cells suppress function of dendritic cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008;16:164-9.
30. Kerdiles YM, Stone EL, Beisner DR, et al. Foxo transcription factors control regulatory T cell development and function. Immunity. 2010;33:890-904.
31. Grossman WJ, Verbsky JW, Barchet W, et al. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity. 2004;21:589-601.
32. Cao X, Cai SF, Fehniger TA, et al. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity. 2007;27:635-46.
33. Koch MA, Tucker-Heard G, Perdue NR, et al. The transcription factor T-bet controls regulatory T cell homeostasis function during type 1 inflammation. Nat Immunol. 2009;10:595-602.
34. Zheng Y, Chaudhry A, Kas A, et al. Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control T(H)2 responses. Nature. 2009;458:351-6.
35. Zhou L, Lopes JE, Chong MM, et al. TGF-beta-induced Foxp3 inhibits TH17 cell differentiation by antagonizing ROR_t function. Nature. 2008;453:236-40.
36. Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+ CD25+ T cell mediated suppression by dendritic cells. Science. 2003;299:1033-6.
37. Sutmuller RP, den Brok MH, Kramer M, et al. Toll-like receptor 2 controls expansion and function of regulatory T cells. J Clin Invest. 2006;116:485-94.
38. Cerutti A, Rescigno M. The biology of intestinal immunoglobulin A responses. Immunity. 2008;28:740-50.
39. Vargas-Rojas MI, Crispín JC, Richaud-Patin Y, et al. Quantitative and qualitative normal regulatory T cells are not capable of inducing suppression in SLE patients due to T-cell resistance. Lupus. 2008;17:289-94.
40. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease. Medical Communications Resources.
41. Ferhani N, Letuve S, Kozhich A, et al. Expression of highmobility group box 1 and of receptor for advanced glycation end products in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;181:917-27.
42. Lommatzsch M, Cicko S, Muller T, et al. Extracellular adenosine triphosphate and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;181:928-34.
43. Cicko S, Lucattelli M, Muller T, et al. Purigenic receptor inhibition prevents the development of smoke-induced lung injury and emphysema. J Immunol. 2010;185:688-97.
44. Chen ZH, Kim HP, Sciurba FC, et al. Egr-1 regulates autophagy in cigarette smoke-induced chronic obstructive pulmonary disease. PLoS One. 2008;3:e3316.
45. Blidberg K, Palmberg L, Dahlén B, et al. Increased neutrophil migration in smokers with or without chronic obstructive pulmonary disease. Respirology. 2012;17:854-60.
46. Takeyama K, Dabbagh K, Jeong S, et al. Oxidative stress causes mucin synthesis via transactivation of epidermal growth factor receptor: Role of neutrophils. J Immunol. 2000;164: 1546-52.
47. Segura-Valdez L, Pardo A, Gaxiola M, et al. Upregulation of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell death in COPD. Chest. 2000;117:684-94.
48. Domínguez-Fandos D, Peinado VI, Puig-Pey R, et al. Pulmonary inflammatory reaction and structural changes induced by cigarette smoke exposure in the Guinea pig. COPD. 2012;9: 473-84.
49. Lommatzsch M, Bratke K, Knappe T, et al. Acute effects of tobacco smoke on human airway dendritic cells in vivo. Eur Respir J. 2012;35:1130-6.
50. Freeman CM, Martinez FJ, Han MK, et al. Lung dendritic cell expression of maturation molecules increases with worsening chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;180:1178-88.
51. Heath WR, Carbone FR. Dendritic cell subsets in primary and secondary T cell responses at body surfaces. Nat Immunol. 2009;10:1237-44.
52. Roos-Engstrand E, Pourazar J, Behndig AF, et al. Cytotoxic T cells expressing the co-stimulatory receptor NKG2 D are increased in cigarette smoking and COPD. Respir Res. 2010;11:128.
53. Maeno T, Houghton AM, Quintero PA, et al. CD8+ T cells are required for inflammation and destruction in cigarette smokeinduced emphysema in mice. J Immunol. 2007;178:8090-6.
54. Hodge S, Hodge G, Nairn J, et al. Increased airway granzyme b and perforin in current and ex-smoking COPD subjects. COPD. 2006;3:179-87.
55. Imaoka H, Hoshino T, Takei S, et al. Interleukin-18 production and pulmonary function in COPD. Eur Respir J. 2008;31:287-97.
56. Borchers MT, Wesselkamper SC, Harris NI, et al. CD8+ T cells contribute to macrophage accumulation and airspace enlargement following repeated irritant exposure. Exp Mol Pathol. 2007;83:301-10.
57. Chen C, Shen Y, Ni CJ, et al. Imbalance of circulating Tlymphocyte subpopulation in COPD and its relationship with CAT performance. J Clin Lab Anal. 2012;26:109-14.
58. Majo J, Ghezzo H. Lymphocyte population and apoptosis in the lungs of smokers and their relation with emphysema. Eur Respir J. 2001;17:946-53.
59. Whittaker L, Niu N, Temann UA, et al. Interleukin-13 mediates a fundamental pathway for epithelial mucus induced by CD4 T cells and interleukin-9. Am J Respir Cell Mol Biol. 2002;27:593-602.
60. Kang MJ, Lee CG, Cho SJ, et al. IFN-gamma-dependent DNA injury and/or apoptosis are critical in cigarette smoke-induced murine emphysema. Proc Am Thorac Soc. 2006;3:517-8.
61. Pan HF, Leng RX, Feng CC, et al. Expression profiles of Th17 pathway related genes in human systemic lupus erythematosus. Mol Biol Rep. 2013;40:391-9.
62. Li HJ, Zhang CQ, Yu CX, et al. Roles of Th17 lymphocytes and inflammatory cytokines in airway inflammation exacerbation of murine asthmatic model. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2012;28:1126-38.
63. Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6:1123-32.
64. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:2645-53.
65. Demoor T, Bracke KR, Maes T, et al. Role of lymphotoxin-alpha in cigarette smoke-induced inflammation and lymphoid neogenesis. Eur Respir J. 2009;34:405-16.
66. Brusselle GG, Demoor T, Bracke KR, et al. Lymphoid follicles in (very) severe COPD: Beneficial or harmful? Eur Respir J. 2009;34:219-30.
67. Randall TD. Bronchus-associated lymphoid tissue (BALT) structure and function. Adv Immunol. 2010;107:187-241.
68. Cosio MG, Saetta M, Agusti A. Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med. 2009;360:2445-54.
69. Xiong XZ, Jin Y, Zhou Q, et al. Correlation between FoxP3+ regulatory T cells and chronic obstructive pulmonary disease. Zhonghua Yi Xue Za Zhi. 2008;88:471-4.
70. Lee SH, Goswami S, Grudo A, et al. Antielastin autoimmunity in tobacco smoking-induced emphysema. Nat Med. 2007;13:567-9.
71. Isajevs S, Taivans I, Strazda G, et al. Decreased FOXP3 expression in small airways of smokers with COPD. Eur Respir J. 2009;33:61-7.
72. Plumb J, Smyth JC. Role of regulatory T-cells in chronic obstructive pulmonary disease. Annals of Respiratory Medicine. 2009;33:61-7.
73. Roos-Engstrand E, Pourazar J, Behndig AF, et al. Expansion of CD4+CD25+ helper T cells without regulatory function in smoking and COPD. Respir Res. 2011;12:74.
74. Ito K, Ito M, Elliott WM, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med. 2005;352:1967-76.